Libtayo® (cemiplimab-rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse Cancers
Share this article TARRYTOWN, N.Y., May 19, 2021 /PRNewswire/ -- Presentations include first positive clinical data for the fianlimab (LAG-3 inhibitor) and Libtayo combination in advanced melanoma Regeneron will host an investor webcast on Monday, June 7 to provide further updates across its oncology portfolio Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the company will share a range of presentations for its PD-1 inhibitor Libtayo ® (cemiplimab-rwlc) and broader oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8,...
Source: prnewswire.com